The U.S. Food and Drug Administration (FDA) has issued a Letter to Health Care Providers (LHCP) alerting clinicians to a current supply disruption affecting stereotactic breast biopsy needles (FDA product code KNW), a critical diagnostic tool used in breast cancer screening and diagnosis. The agency notification aims to ensure healthcare providers are aware of potential procurement challenges and can plan patient care accordingly.
- What are stereotactic breast biopsy needles?
- Supply chain vulnerabilities in medical device manufacturing
- Clinical implications and patient care continuity
- Frequently asked questions
- What should I do if my breast biopsy is scheduled during this shortage?
- Are there alternative methods for breast tissue diagnosis during a needle shortage?
- How long is the stereotactic breast biopsy needle shortage expected to last?
- Looking ahead: strengthening diagnostic device resilience
Key takeaways
- Stereotactic breast biopsy needles (product code KNW) are experiencing documented supply disruptions
- The FDA has formally notified healthcare providers through an official Letter to Health Care Providers
- Providers should implement contingency planning for diagnostic breast procedures during the shortage
- Access to breast biopsy equipment affects cancer diagnosis timelines and patient care continuity
Device shortages impact healthcare access pathways
When critical diagnostic equipment becomes unavailable, patient care timelines are delayed across multiple care settings
Source: FDA Letter to Health Care Providers | Georgian Medical Journal News
What are stereotactic breast biopsy needles?
Stereotactic breast biopsy needles are precision medical devices used to obtain tissue samples from breast lesions identified on imaging studies. According to the FDA’s medical devices classification database, these instruments are essential for minimally invasive diagnostic procedures that help differentiate benign from malignant breast lesions, enabling early cancer detection and treatment planning.
The procedure uses three-dimensional imaging guidance (stereotaxis) to precisely locate and sample suspicious breast tissue, making it a standard diagnostic approach in breast imaging centers and surgical facilities. When these needles become unavailable, radiologists and surgeons must defer diagnostic procedures or shift patients to alternative, often more invasive sampling methods such as surgical excisional biopsy.
Supply chain vulnerabilities in medical device manufacturing
Device shortages in diagnostic imaging reflect broader supply chain vulnerabilities in medical device manufacturing, a pattern documented across the healthcare sector. The FDA’s postmarket surveillance system monitors device availability, and formal notifications through Letters to Health Care Providers signal that disruptions exceed routine, temporary delays.
Healthcare providers receiving the FDA’s formal notification are expected to implement contingency protocols, including inventory assessment, identification of alternative diagnostic pathways, and communication with patients about potential scheduling delays. The notification mechanism allows the FDA to ensure provider awareness without mandating specific corrective actions from manufacturers or facilities.
Clinical implications and patient care continuity
Breast biopsy needle shortages directly impact cancer diagnosis timelines, which have measurable clinical significance. Delays in diagnostic confirmation can extend the period of diagnostic uncertainty for patients and may necessitate use of more invasive sampling procedures, increasing patient burden and healthcare costs. Facilities managing this disruption must balance supply constraints with clinical urgency, prioritizing patients with high-risk lesions while deferring lower-suspicion cases where clinically appropriate.
Healthcare systems should contact their supply chain managers and device representatives to assess local inventory status and explore alternative device options that remain available. Radiology departments may need to adjust scheduling to optimize available needle inventory and coordinate with pathology labs to manage case volume. Communication with patients about potential delays in diagnostic procedures is essential to manage expectations during the shortage period.
The FDA has issued a formal Letter to Health Care Providers regarding disruptions in availability of stereotactic breast biopsy needles (product code KNW), requiring providers to implement care continuity protocols during the supply shortage.
— U.S. Food and Drug Administration, Medical Devices Division (2024)
What this means
Frequently asked questions
What should I do if my breast biopsy is scheduled during this shortage?
Contact your imaging facility or radiologist’s office to confirm your appointment status. Many facilities maintain adequate inventory despite the broader shortage. If your facility is affected, your healthcare team will reschedule your procedure or discuss alternative diagnostic approaches. Do not delay if you have symptoms or high-risk imaging findings—communicate with your provider about clinical urgency.
Are there alternative methods for breast tissue diagnosis during a needle shortage?
Yes, although they vary by clinical situation and facility capability. Options include surgical excisional biopsy (more invasive but provides definitive tissue diagnosis), core needle biopsy using alternative equipment, or repeat imaging follow-up for lower-suspicion lesions. Your radiologist will recommend the most appropriate approach based on your specific clinical scenario and available resources.
How long is the stereotactic breast biopsy needle shortage expected to last?
The FDA’s Letter to Health Care Providers does not specify an expected resolution timeline. Supply disruptions in medical devices vary widely depending on manufacturing capacity, supply chain restoration, and demand levels. Contact your facility’s supply chain department for updates on local availability and anticipated restocking dates.
Looking ahead: strengthening diagnostic device resilience
This clinical alert underscores the importance of medical device supply chain planning in healthcare systems. As diagnostic imaging continues to advance, ensuring reliable access to precision biopsy equipment remains essential for timely cancer detection. Healthcare facilities should use this disruption as an opportunity to assess supply chain vulnerabilities, establish relationships with multiple device suppliers, and participate in quality and safety initiatives that address device availability. The FDA continues to monitor the situation and will provide updates as supply normalizes.
Source: FDA Letter to Health Care Providers: Disruptions in Availability of Breast Biopsy Needles
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
